Applied BioCode currently has more than 50 diagnostic testing products with FDA approval, including the one detecting SARS CoV-2, it aims to enrich its product portfolio up to 100 by three years, given solid demands for molecular and immunology diagnostic tests globally.
As part of the company’s ‘dual-track’ strategy, licensing will be the area of focus as per Applied BioCode. It has licensed IDEXX Laboratories, the global leader in veterinary diagnostics, to use its patented BMB platform for 50 million specimens IDEXX receives a year. This platform allows to test 15 items at a time, compared to one per specimen detected by a platform which the laboratory used.
The company has developed over 40 tests, looking to three more in the coming year or in three years’ time. There will be assays for urethritis, allergies, STDs and for haematology and oncology.
About Applied BioCode
Applied BioCode develops, manufactures, and commercializes multiplex diagnostic testing products.
The company has currently received FDA Clearance for the BioCode® MDx-3000 system with a 17-plex Gastrointestinal Pathogen Panel (GPP) and a 17-plex Respiratory Pathogen Panel(RPP). The Gastrointestinal Pathogen Panel (GPP) has also obtained the CE-Mark for use in European countries conforming to CE-Mark regulations. Applied BioCode, Inc. has also submitted its BioCode® SARS-CoV-2 Assay to the FDA for Emergency Use Authorization (EUA). Pre-EUA Submission Number: PEUA200355
Applied BioCode, Inc. also partners with a variety of diagnostic and pharmaceutical companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary diagnostics.
Source in Chinese: https://news.cnyes.com/news/id/4664633